Skip to main content

Table 1 Baseline demographic characteristics in the double-blind controlled study

From: ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension

 

Placebo

ABT-126 25 mg

ABT-126 50 mg

ABT-126 75 mg

Donepezil 10 mg

All subjects

Number of subjects

104

77

107

73

75

436

 Age (years), mean ± SD

73.2 ± 7.39

73.0 ± 7.62

73.9 ± 8.26

76.2 ± 8.14

75.1 ± 7.75

74.2 ± 7.89

 Age < 75 years, n (%)

59 (56.7)

37 (48.1)

50 (46.7)

30 (41.1)

30 (40.0)

206 (47.2)

 Age ≥ 75 years, n (%)

45 (43.3)

40 (51.9)

57 (53.3)

43 (58.9)

45 (60.0)

230 (52.8)

 Female, n (%)

65 (62.5)

40 (51.9)

68 (63.6)

52 (71.2)

40 (53.3)

265 (60.8)

 Male, n (%)

39 (37.5)

37 (48.1)

39 (36.4)

21 (28.8)

35 (46.7)

171 (39.2)

 White, n (%)

91 (87.5)

75 (97.4)

96 (89.7)

64 (87.7)

70 (93.3)

396 (90.8)

 BMI (kg/m2), mean ± SD

26.2 ± 3.88

27.1 ± 4.91

26.0 ± 4.98

25.5 ± 4.62

25.0 ± 4.27

26.0 ± 4.57

 Age at AD symptom onset (years), mean ± SD

69.6 ± 7.66

69.2 ± 8.51

70.2 ± 8.67

72.3 ± 7.97

71.2 ± 8.24

70.4 ± 8.25

 Years since AD symptom onset,a mean ± SD

3.7 ± 2.61

4.1 ± 2.96

3.9 ± 3.11

4.2 ± 2.67

4.2 ± 2.45

4.0 ± 2.78

 Age at AD diagnosis (years), mean ± SD

72.1 ± 7.60

71.5 ± 8.10

72.5 ± 8.64

74.8 ± 8.30

73.6 ± 7.91

72.8 ± 8.16

 Years since AD diagnosis, mean ± SD

1.1 ± 1.79

1.5 ± 1.91

1.4 ± 2.37

1.5 ± 1.96

1.6 ± 1.92

1.4 ± 2.02

 Family history of AD, n (%)

22 (21.2)

20 (26.0)

23 (21.5)

6 (8.2 %)

10 (13.3)

81 (18.6)

 ADAS-Cog (11-item),b mean ± SD

26.1 ± 10.98

24.6 ± 11.45

25.6 ± 11.32

27.2 ± 9.81

27.9 ± 12.08

26.2 ± 11.16

 MMSE score, mean ± SD

19.1 ± 4.00

20.0 ± 4.09

18.6 ± 4.03

18.6 ± 3.87

18.4 ± 4.42

18.9 ± 4.09

Number of subjects

92

66

97

63

64

382

 APOE ε4 positive, n (%)

37 (40.2)

34 (51.5)

48 (49.5)

27 (42.9)

32 (50.0)

178 (46.6)

  1. aTime from onset of AD symptoms or diagnosis to first dose of study drug
  2. bBaseline results based on a total of 435 subjects
  3. AD Alzheimer’s dementia, ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive subscale, APOE apolipoprotein E, BMI body mass index, MMSE Mini-Mental Status Examination, SD standard deviation